Serum levels of soluble CD26 and CD30 and their clinical significance in patients with rheumatoid arthritis
RHEUMATOLOGY INTERNATIONAL, vol.32, no.12, pp.3857-3862, 2012 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 32 Issue: 12
- Publication Date: 2012
- Doi Number: 10.1007/s00296-011-2302-3
- Journal Name: RHEUMATOLOGY INTERNATIONAL
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.3857-3862
- Keywords: Rheumatoid arthritis, Disease activity, CD26, CD30, DIPEPTIDYL-PEPTIDASE-IV, CD4(+) T-CELLS, SYNOVIAL-FLUID, DISEASE-ACTIVITY, FUNCTIONAL-ROLE, EXPRESSION, INFLAMMATION, CYTOKINES, OSTEOARTHRITIS, PATHOGENESIS
- Ondokuz Mayıs University Affiliated: Yes
Abstract
The aim of this study was to assess serum levels and clinical significance of soluble CD26 (sCD26) and soluble CD30 (sCD30) in patients with rheumatoid arthritis (RA). Forty-eight patients with RA and 30 healthy controls were enrolled. Serum sCD26 and sCD30 levels were measured using ELISA. Serum sCD26 levels were significantly lower (P = 0.011), whereas sCD30 levels were higher (P = 0.008) in patients with RA than controls. Serum levels of sCD30 correlated significantly with clinical and laboratory parameters of disease activity like erythrocyte sedimentation rate, C-reactive protein, disease activity scores-28 and health assessment questionnaire score; however, sCD26 levels did not correlate any of these activity parameters. These results suggest that serum sCD30 levels increased and correlated significantly with disease activity, indicating a novel follow-up parameter in RA. Serum levels of sCD26 may be lessen but not related to disease activity in RA.